title: [Coffee and cancer].
authors.affiliation: IDIBAPS. Institut d'Investigació August Pi i Sunyer. Departamento de Bioquímica y Biología Molecular. Universidad de Barcelona. Barcelona. España. rfranco@ub.edu
authors.forename: Rafael
authors.initials: R
authors.lastname: Franco
mesh_terms: D000241:Adenosine / Q000037:antagonists & inhibitors*; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002110:Caffeine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003069:Coffee / Q000009:adverse effects / Q000737:chemistry; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000098:blood supply / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010766:Phosphorylation / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D043683:Receptors, Adenosine A2 / Q000502:physiology; D013805:Theobromine / Q000627:therapeutic use; D013806:Theophylline / Q000627:therapeutic use
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D016588:Anticarcinogenic Agents; D003069:Coffee; D009363:Neoplasm Proteins; D043683:Receptors, Adenosine A2; D002110:Caffeine; D013806:Theophylline; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt; D000241:Adenosine; D013805:Theobromine